New hope for hard-to-treat cancers: experimental drug targets HER2-positive tumors
NCT ID NCT07309770
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called trastuzumab rezetecan in people with advanced solid tumors that have stopped responding to standard therapies. The drug is given every three weeks to 90 participants divided into three groups based on their cancer type. Researchers will measure how many tumors shrink or disappear and track side effects and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trastuzumab rezetecan (SHR-A1811), an antibody-drug conjugate
- What this could lead to
- If successful, this could offer a new treatment option for people with HER2-positive advanced solid tumors who have run out of standard therapies.
- What could go wrong
- This is an early-phase (Phase II) study with a small number of participants (90). It may not show enough benefit or could have side effects that limit its use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Genetic blueprint of tumors may guide smarter cancer treatment
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers